Navigation Links
BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
Date:4/14/2009

WOBURN, Mass., April 14 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that its OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 study with OncoVEX (GM-CSF) in previously treated patients with Stage III and Stage IV melanoma had initiated. The study has commenced recruiting patients in the U.S. with sites in the United Kingdom, Germany and Australia due to open later in the year. Further details on this study can be found at www.oncovexgmcsf.com and at www.clinicaltrials.gov.

Dr Robert Coffin, Founder and Chief Technology Officer of BioVex Inc said:

"The treatment options for patients with recurrent or metastatic melanoma are currently very limited, with no therapy being approved or recognized to be effective in the second line setting and beyond. Currently, there are also very few late stage or pivotal clinical studies available for patients who have failed first line therapy. The initiation of this study, following the highly encouraging data generated in Phase 2, is therefore a significant milestone on the path towards meeting this major unmet need, and towards the approval of OncoVEX (GM-CSF) in this first indication."

OPTiM Phase 3 Trial Design

The OPTiM trial is a multi-national, open label, randomized Phase 3 study designed to assess the efficacy and safety of treatment with OncoVEX (GM-CSF) as compared to subcutaneously administered GM-CSF in patients with unresectable stage III (b-c) and Stage IV (M1a-c) disease. Patients will have received at least one prior therapy for active disease which includes any type of therapy including investigational drugs. A total of 360 patients will be enrolled (240 to
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. BioVex Raises $40 Million in First Close of Series F Financing
2. BioVex to Present at the UBS Global Life Sciences Conference
3. BioVex Closes Second Round of Series E Financing
4. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
5. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
6. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
7. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
8. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
9. SenesTech, Inc. Commences Product Registration Process With Australian Government
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... 2013 The JM Internet Group (web: ... has proudly announced that the company's YouTube channel on ... 175,000 views on YouTube. The company uses YouTube as ... tips and training for small businesses with much success. ... YouTube tips helpful for their SEO strategies", explained Jason ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Dr. Sparano ... and Women’s Health at the Albert Einstein College of ... at the Montefiore Medical Center. He is also ... Center and leads the Einstein Breast Cancer Working Group, ... translational breast cancer research. He also serves as Vice ...
(Date:5/17/2013)... transplant recipient,s immune system identifies the transplanted organ as ... that T cells, the immune cells that mediate rejection, ... in order to migrate to the transplanted organ. In ... , Fadi Lakkis and colleagues at the University of ... T cells is not required for migration. Instead, these ...
(Date:5/17/2013)... 17, 2013 - Elsevier, a world-leading provider of scientific, ... the publication of a recent study in ... blastocysts showing that those with an abnormal chromosomal composition ... have developed to blastocysts, thereby classifying the risk of ... the same group has undertaken a retrospective study, using ...
Breaking Biology Technology:YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3
... lead sponsorship of the International Genetically Engineered ... by the Massachusetts Institute of Technology (MIT). ... undergraduate teams representing more than 1,000 students ... America, and the U.S. to design and ...
... preliminary data,from a Phase II/III clinical trial of ... heart failure will be presented next,week at a ... Sessions 2008 in New Orleans., John R. ... Francisco, will present the data from the multicenter, ...
... Nov. 3 Verenium Corporation,(Nasdaq: VRNM ), ... and high-performance specialty enzymes, announced today that it,will ... November 10,2008 after market close. In conjunction with ... with live webcast on Monday, November 10 at ...
Cached Biology Technology: The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems 2 The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems 3Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008 2Verenium Corporation to Announce Third Quarter 2008 Financial Results 2Verenium Corporation to Announce Third Quarter 2008 Financial Results 3
(Date:5/17/2013)... Bethesda, MD The Federation of American Societies for ... of National Institutes of Health (NIH) funding trends highlighting ... to support critical research. The FASEB analysis follows a ... Francis Collins, MD, PhD, who testified that the $1.6 ... to sequestration is "having a substantial impact on the ...
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) ... The Society for Developmental Biology (SDB) 72nd Annual ... These awards are meant to promote the entry ... into the mainstream of the basic science community ... at the SDB 2013 Annual Meeting. , Awards ...
(Date:5/16/2013)... MA -- Injectable nanoparticles developed at MIT may ... 1 diabetes to constantly monitor their blood-sugar levels ... were designed to sense glucose levels in the ... of insulin, thereby replacing the function of pancreatic ... Type 1 diabetes. Ultimately, this type of system ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... it tough for Foghat to get much airplay these days, ... in The American Naturalist . Behavioral ecologist Elizabeth ... white-crowned sparrows change over time in response to changing habitats. ... evolution of mating signals in birds. Derryberry says she ...
... University have discovered a previously unknown pathway in plant ... assistant professor in genetics, development and cell biology, examined ... hormone controls the growth of cells. , The brassinosteroids ... plant grows, says Yin. , "Previously, we knew that ...
... for Optimizing CHO Performance,” to feature new supplement ... BIO 2009 International Convention in Atlanta, GA.  , ... b3c newswire / – InVitria’s Director of Cell ... enhancing features of ZAP-CHO, a new media component ...
Cached Biology News:Bird songs change with environment 2ISU researcher identifies genetic pathway responsible for much of plant growth 2InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO 2